Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma

BMC Cancer

Table 2 Univariate analysis of clinicopathologic variables in 100 patients with LSC (log-rank test)

Variable	All cases	Mean survival(months)	Median survival(months)	P value^a
Age (years)^b				0.439
≤ 57	47	47.8	31.0
>57	53	55.4	18.0
Gender				0.538
Female	13	37.4	27.0
Male	87	55.2	25.0
Smoking				0.078
Yes	76	59.4	43
No	24	25.1	15.0
Tumor size^c				0.032
≤ 4.5 cm	59	65.8	48.0
>4.5 cm	41	39.5	18.0
T stage				0.033
T1 And T2	56	63.2	48.0
T3 And T4	44	44.7	14.0
Lymph node				0.000
N0	52	74.7	68.0
N1,N2 And N3	48	31.4	14.0
M stage				0.000
M0	92	59.9	43.0
M1	8	12.1	8.0
Therapy^d				0.103
Therapy1	76	62.2	48.0
Therapy2	19	28.9	21.0
Therapy3	5	19.0	24.0
Relapse				0.713
Yes	30	36.4	24.0
No	70	58.9	43.0
Clinical stage				0.000
I-II	45	89.8	NR
III-IV	55	19.5	11.0
p53R2				0.000
Low expression	42	84.8	NR
High expression	58	34.7	12.0

^aChi-square test
^bMean age
^cMean tumor size
^dTherapy:Therapy1 is Pneumonectomy and lymphadenectomy, Therapy2 is Pneumonectomy;Therapy3 Pneumonectomy and radiotherapy and chemoradiotherapy

ISSN: 1471-2407